QURE Overview
Upcoming Projects (QURE)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (QURE)
-
A second look: Discussing the potential of uniQure's gene therapy AMT-130 and PTC Therapeutics candidate PTC518 in Huntington's Disease.
Tickers: QURE, PTCT
Executed On: Jun 30, 2023 at 12:30 PM EDT -
Discussing the potential of uniQure's gene therapy AMT-130 and PTC Therapeutics candidate PTC518 in Huntington's Disease.
Tickers: QURE, PTCT
Executed On: Jun 27, 2023 at 10:45 AM EDT -
A second look: Discussing the potential of HEMGENIX(etranacogene dezaparvovec-drlb), the first FDA-approved gene therapy for patients with hemophilia B, based on the ongoing HOPE-B trial
Tickers: CSL.XASX, QURE
Executed On: Dec 16, 2022 at 10:30 AM EST -
Discussing the potential of HEMGENIX(etranacogene dezaparvovec-drlb), the first FDA-approved gene therapy for patients with hemophilia B, based on the ongoing HOPE-B trial
Tickers: CSL.XASX, QURE
Executed On: Dec 09, 2022 at 02:15 PM EST -
Discussing the treatment landscape for Huntington's Disease with special attention to PTC 518 and AMT-130
Tickers: QURE, PTCT, IONS, RHHBY
Executed On: Jul 19, 2022 at 08:15 AM EDT
Upcoming & Overdue Catalysts (QURE)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (QURE)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
